Frequent Lupus flares?

Purpose of the study

You or your child may be eligible for this research study, if the following applies to one of you:

Copyright © Clariness, 2006-2021.  All rights reserved. 

If so, you or your child could be eligible for a clinical research study in Systemic Lupus Erythematosus (SLE).

Privacy policyLegal & Privacy

If so, you or your child could be eligible for a clinical research study in Systemic Lupus Erythematosus (SLE).

Frequent Lupus flares?

The purpose of this study is to assess if the investigational study medication dapirolizumab pegol (DZP), used in addition to your SLE medication, may improve your SLE.

  • The immune system uses antibodies (proteins naturally found in the body) to identify and neutralize foreign objects such as pathogenic bacteria and viruses and appropriately directing the immune response against it.
  • In SLE, the immune system is causing inflammation directed against the own body. Antibodies against structures of the own body, so called auto-antibodies, can play a role in this process.
  • Dapirolizumab Pegol (DZP) is an antibody. DZP binds to a molecule called CD40 ligand (CD40L), on the surface of many cells of the immune system which is necessary to facilitate their interactions and communications. By blocking CD40L, these inflammatory cells cannot mature, activate, or produce autoantibodies thus leading to decreased inflammation. In this study, we are trying to find out if DZP might be able to improve the symptoms of SLE.

The study also assesses if DZP is well tolerated when given to you.

Purpose of the study

Double-click to edit this text

Your next steps

What happens after I register?

See if the study may be suitable for you by completing an online questionnaire


Create a free and secure ClinLife account


Have your contact details submitted to a participating site


Be contacted by a participating study center for further information


Systemic Lupus Erythematosus study

 Answer a few questions and see if you or your child may be eligible for participation.


What is ClinLife?

ClinLife is a free and easy-to-use website helping patients worldwide find the most relevant clinical studies suitable to their medical condition. Listing all available studies by disease area or medical condition, it provides an essential link between research sites and people seeking clinical research studies.

Free, non-binding and voluntary 
Registering for this and any future study via ClinLife is free and non-binding:
Taking part in any clinical study is voluntary. You have the right to leave a clinical study at any time, for any reason.

Study Center selection 

Once you’ve successfully completed the online questionnaire, you can to select a study center near you.

Call Center Agent will call you
After you’ve submitted your contact details, a representative from the study center or a ClinLife Call Center Agent will be in contact with you within the next few days.

Additional questions
They will ask you additional questions and answer any questions you may have. The benefits and risks will be explained to you and you will also receive information on the possible allowance.

Appointment Scheduling
If the study center staff determines that the study is suitable for you, they will schedule an appointment with you.

Keep you informed
If the study you are interested in is not suitable for you, we can keep you informed about upcoming studies that might be better suited for you.





There are other requirements. A final decision on whether this research study might be suitable for you or your child will be made after you speak with the study doctor at the research site. The study doctor will explain the benefits and risks of participation in this research study.

  • You are at least 18 years old
  • One of you have persistent or relapsing burdensome symptoms of your SLE under your current SLE medication

Double-click to edit this text

Who may participate in this study?

Reimbursement, expenses and insurance

You will not be compensated for taking part in this study. You can receive reimbursement for travel costs for this study and you may receive a reimbursement per study visit.

You will receive all study-related care at no cost. This includes the study drug as well as any visits to your study doctor’s office.

You will be covered by insurance held by the sponsor of the study.

Additional Information

  • Screening Period (2 weeks before the treatment starts). 
  • Treatment Period (48 weeks) during which you will receive treatment for the first 44 weeks. 
  • Safety Follow-up Period (6 weeks).

You may not have a direct health benefit from participating in this study. DZP is an experimental drug and there is no guarantee that your SLE will get better with DZP. In addition, instead of DZP, you may receive a placebo and your SLE medication.

However, DZP may improve your SLE activity. The information learned from this study may help to learn more about the safety and tolerability of DZP. Further data from this study may serve to understand SLE better and how to treat it better.

You will be informed of any significant new findings developed during the course of the study that may affect your willingness to continue participation.

At least 450 people at about 280 study centers throughout approximately 30 countries worldwide are expected to take part in this study.

The study has 3 periods:

Double-click to edit this text